A 66-year-old man with Barrett's esophagus presented for evaluation of a 2-cm sporadic duodenal bulb tubulovillous adenoma with high-grade dysplasia (HGD) (Fig. 1) . EUS revealed sparing of the muscularis propria and the submucosa. Initial therapy consisted of piecemeal EMR (Duette Kit, Cook Medical, Bloomington, Ind). When residual lesions were found on follow-up examination, EMR was reattempted, but the lesion could not be lifted with submucosal injection, likely because of scar tissue. The patient then underwent more than 2 years of repeated applications of argon plasma coagulation (APC) and radiofrequency ablation (RFA) (HALO, now Barrx, Medtronic, Minneapolis, Minn), but the lesion persisted ( Fig. 2) and developed a single minute focus of intramucosal carcinoma. The patient refused surgical resection.
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Next, cryoablation (Coldplay CryoBalloon, C2 Therapeutics, Redwood, Calif) was applied to the lesion over 2 endoscopic sessions, with each treatment lasting up to 12 seconds (Figs. 3A-C; Video 1, available online at www. VideoGIE.org). Our intention was eradication of the lesion. Removal with hot avulsion forceps was considered, but we opted for cryoablation because we hoped for more controlled treatment over a larger lesion area. Surveillance EGD (Fig. 4) after the first session revealed persistent HGD with focal complexity. A second session was performed 10 weeks after the first session. Follow-up EGD ( Fig. 5 ) with extensive biopsies 1 month after the second session showed no evidence of dysplasia or carcinoma. There were no adverse events. A subsequent surveillance EGD was planned 3 to 6 months after the second cryoablation session.
To our knowledge, this is the first use of cryoablation on a duodenal neoplasm. It is also the first use of balloonassisted cryoablation in the duodenum. First used in the GI tract in 1999, 1 cryoablation has been used to treat duodenal arteriovenous malformations, radiation-induced duodenitis, radiation-induced proctitis, 2 and gastric antral vascular ectasia. 3 We found only 1 report of its use in the duodenum for any reason.
2 It has been used on the duodenal papilla in a porcine model. 4 Endoscopic cryoablation is most commonly used to treat esophageal neoplasia and preneoplasia. Limited evidence from industry-supported high-quality studies have reported downgrading of esophageal HGD in 68% to 97% of patients. [5] [6] [7] In our case, 2 sessions of cryoablation were effective in ablating duodenal HGD and carcinoma that were refractory to multiple other modalities.
The risks include perforation, stricture, bleeding, and chest pain. Spray-type cryoablation in the esophagus has been shown to cause cryonecrosis reaching the Written transcript of the video audio is available online at www.VideoGIE.org. submucosa. 8 In comparison with its use for esophageal lesions, the risk of perforation may be greater, given the thinner duodenal walls. Even though our patient had undergone multiple prior interventions, including EMR, RFA, and APC before cryotherapy, cryoablation did not result in perforation or any other adverse event.
The American Society for Gastrointestinal Endoscopy (ASGE) makes no specific recommendations regarding cryotherapy for the management of Barrett's esophagus 9 but does recognize a potential role for cryoablation and other therapies for the ablation of residual tissue after resection. 10 The American Gastroenterological Association guidelines cite a dearth of high-quality studies and lack of long-term follow-up; they do not recommend cryotherapy.
11
Based on a small number of high-quality studies, the ASGE guidelines recommend EMR for duodenal adenomas distal to the bulb and APC for destruction of remaining dysplastic tissue. 12 There are no recommendations regarding cryoablation in the duodenum.
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